Recurrent small cell lung cancer: Update
- 28 February 2003
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 30 (1), 72-78
- https://doi.org/10.1053/sonc.2003.50014
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Phase II Comparator Study of Oral Versus Intravenous Topotecan in Patients With Chemosensitive Small-Cell Lung CancerJournal of Clinical Oncology, 2001
- Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung CancerJournal of Clinical Oncology, 1999
- Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer.Journal of Clinical Oncology, 1998
- A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancerBritish Journal of Cancer, 1998
- Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.Journal of Clinical Oncology, 1997
- Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.Journal of Clinical Oncology, 1996
- Phase II Study of Vinorelbine in Heavily Previously Treated Small Cell Lung CancerOncology, 1996
- Activity of docetaxel (Taxotere) in small cell lung cancerEuropean Journal Of Cancer, 1994
- Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patientsEuropean Journal Of Cancer, 1993
- CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.Journal of Clinical Oncology, 1992